Vivan Therapeutics Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
21
- Latest Deal Type
-
Accelerator/Inc
- Investors
-
16
Vivan Therapeutics General Information
Description
Developer of personalized therapeutics designed to transform cancer care. The company's technology follows the personal discovery process (PDP), a massive clinical trial for a single patient, where the genetic complexity of each patient's tumor network is engineered into a group of fruit flies and robotics are used to evaluate FDA-approved drugs, including non-cancer drugs, enabling cancer patients with better treatment recommendations and developing new diagnostics and decision support tools to make cancer treatment more effective.
Contact Information
Website
www.vivantx.comCorporate Office
- Unit 3, Part First Floor
- The Westworks, White City Place, 195 Wood Lane
- London W12 7FQ
- England, United Kingdom
Corporate Office
- Unit 3, Part First Floor
- The Westworks, White City Place, 195 Wood Lane
- London W12 7FQ
- England, United Kingdom
Vivan Therapeutics Timeline
Vivan Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 16. Accelerator/Incubator | Completed | Generating Revenue | ||||
| 15. Accelerator/Incubator | 14-Jul-2025 | Completed | Generating Revenue | |||
| 14. Accelerator/Incubator | 10-Feb-2025 | Completed | Generating Revenue | |||
| 13. Accelerator/Incubator | 01-Jan-2024 | Completed | Generating Revenue | |||
| 12. Accelerator/Incubator | 01-Jan-2024 | Completed | Generating Revenue | |||
| 11. Accelerator/Incubator | Completed | Generating Revenue | ||||
| 10. Later Stage VC (Series 2) | 30-Dec-2024 | Completed | Generating Revenue | |||
| 9. Grant | 05-Oct-2022 | Completed | Generating Revenue | |||
| 8. Grant | 05-Oct-2020 | $469K | $1.46M | Completed | Generating Revenue | |
| 7. Early Stage VC | $74.5K | $1.46M | Completed | Pre-Clinical Trials |
Vivan Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Preference | ||||||||
| Preference | ||||||||
| Preference | ||||||||
| Ordinary A | ||||||||
| Preference | ||||||||
| Ordinary A | ||||||||
| Preference | ||||||||
| Preference | ||||||||
| Ordinary | 4,062 | $0.001264 | $103.14 | $103.14 | 1x | $103.14 | 1.84% | |
| Preference | 297 | $0.001264 | $103.67 | $103.67 | 1x | $103.67 | 0.13% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Vivan Therapeutics Comparisons
Industry
Financing
Details
Vivan Therapeutics Competitors (1)
One of Vivan Therapeutics’s competitors is CureMatch, a Venture Capital-Backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| CureMatch | Venture Capital-Backed | San Diego, CA |
Vivan Therapeutics Patents
Vivan Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4444299-A1 | A combination treatment for cancer | Pending | 06-Dec-2021 | ||
| US-20250032494-A1 | A combination treatment for cancer | Pending | 06-Dec-2021 | ||
| WO-2023105286-A1 | A combination treatment for cancer | Inactive | 06-Dec-2021 | ||
| EP-4333818-A1 | Model optimized drug and drug combinations for treating cancers | Inactive | 04-May-2021 | ||
| US-20240216546-A1 | Model optimized drug and drug combinations for treating cancers | Pending | 04-May-2021 | A61K49/0008 |
Vivan Therapeutics Signals
Vivan Therapeutics Investors (16)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Nevcap | Accelerator/Incubator | Minority | ||
| Hub71 | Accelerator/Incubator | Minority | ||
| Arben Ventures | Venture Capital | Minority | ||
| Freya Ventures | Venture Capital | Minority | ||
| Reflect Ventures | Venture Capital | Minority |
Vivan Therapeutics FAQs
-
When was Vivan Therapeutics founded?
Vivan Therapeutics was founded in 2018.
-
Where is Vivan Therapeutics headquartered?
Vivan Therapeutics is headquartered in London, United Kingdom.
-
What is the size of Vivan Therapeutics?
Vivan Therapeutics has 21 total employees.
-
What industry is Vivan Therapeutics in?
Vivan Therapeutics’s primary industry is Biotechnology.
-
Is Vivan Therapeutics a private or public company?
Vivan Therapeutics is a Private company.
-
What is Vivan Therapeutics’s current revenue?
The current revenue for Vivan Therapeutics is .
-
How much funding has Vivan Therapeutics raised over time?
Vivan Therapeutics has raised $5.97M.
-
Who are Vivan Therapeutics’s investors?
Nevcap, Hub71, Arben Ventures, Freya Ventures, and Reflect Ventures are 5 of 16 investors who have invested in Vivan Therapeutics.
-
Who are Vivan Therapeutics’s competitors?
CureMatch is a competitor of Vivan Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process